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TARGETED TRIPLE DRUG REGIMEN FOR THE TREATMENT OF PROSTATE CANCER 
 
 
An Abstract of the Thesis by 
Tanuja Tummala 
 
 
Prostate cancer is the most common amongst men. According to ACS 2018 statistics, 
about 164,690 new cases appear and 29,430 deaths occur. Nearly 6 in 10 cases are diagnosed in 
men over 50 years of age and often there are no early symptoms. The treatment options include 
surgery, chemotherapy, hormonal therapy and/or radiation and it can often be treated successfully. 
However, the poor management and adverse effects demanded ways to find better treatment 
option. Towards the development of a personalized medicine for prostate cancer treatment, we 
proposed to design prostate cancer targeting magnetic nanoplatform. This integrates various key 
components such as combination of drugs, imaging agents, targeting ligands and targeted delivery 
of these cargos in high concentrations to tumor. A triple drug regimen of Oxaliplatin, Irinotecan and 
5-Flurouracil was used, which was already known to be effective in the treatment of colorectal 
cancer and pancreatic cancer. These three drugs were encapsulated in folate conjugated magnetic 
nanoparticles and tremendous effect of cell death via oxidative stress in LNCaP cells was observed. 
The synthesis of magnetic nanoparticles, surface conjugation with folic acid using “Click” chemistry, 
encapsulations of cargos and their characterization were discussed in detail. Having folate 
conjugated magnetic nanomedicine, the drug delivery was targeted to prostate cancer and had no 
to minimal toxic effects on the healthy cells. Individual mechanism of the drugs and their synergistic 
effect in the treatment was evaluated by performing optical microscopy, magnetic resonance 
imaging experiments as well as cell-based assays such as ROS, apoptosis and necrosis, 
cytotoxicity, migration, and comet. This study showed us that the targeted nanoformulation which 
we designed was successful in exhibiting the toxic effects on a tumor cell. 
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CHAPTER I 
 
 
IRON OXIDE NANOPARTICLES IN NANOMEDICINE FOR THE DIAGNOSIS AND 
TREATMNENT OF CANCER: A BRIEF OVERVIEW 
                                                                               
                                                                               
1 INTRODUCTION:  
Cancer is the most frightful disease in the world characterized by assemblage of many 
diseases. According to the American Cancer Society Cancer facts and figures 2018, it was reported 
that 87% of the cancer cases diagnosed in United States are in people of age 50 or older.1 There are 
many known causes like smoking, unhealthy diet, lack of physical exercise, family history which may 
lead to the development of cancer. It was stated in a study by the American cancer society 
epidemiologists that 42% of the newly diagnosed cancer cases in 2018 are potentially avoidable.1 Early 
detection and treatment, as well as a decline in smoking habits showed a drop of 26% of cancer cases 
for lung, colorectal, breast and prostate cancers from the years 1991-2015.1 Cancer staging defines 
the degree of cancer at the time of diagnosis, which is essential for optimizing therapy and measuring 
prognosis. Several kinds of conventional treatment routes including chemotherapy, immunotherapy, 
hormone therapy, stem cell transplant, precision medicine, surgery, radiation therapy are available. The 
major draw backs of these conventional treatment approaches include harmful radiation use of 
hydrophobic anti-cancer drugs which have poor solubility, biocompatibility, and their effect on healthy 
cells finds difficulty in providing a better therapeutic effect.2 Many studies are going all over the world 
to treat the cancer by minimizing the toxic effects to non-cancerous cells. In this respect, the 
nanomedicine plays a key role in enhancing the therapeutic efficacy of the anti-cancer drugs. The 
development of targeted drug delivery paved the path for cancer treatment with low toxicity to the 
healthy cells, targetability, improved bioavailability, specificity etc. Sechi et.al., conducted a study and 
the results presented that 43% people consider using nanotechnology for biomedical applications.3 
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There are many nanoplatforms for the cancer theranostics. Amongst all, iron oxide nanoparticles are 
used by many researchers because of their improved theranostic approach, magnetic properties, and 
biodegradability.  
1.1 Iron oxide nanoparticles: Iron oxide nanoparticles fall under the category of magnetic 
nanoparticles, which are the chief class of nanoscale materials in current theranostics.4 The capability 
of the iron oxide nanoparticles to work together at both cellular and molecular levels and their unique 
physical properties made perfect for use in several biomedical applications such as MRI contrast 
agents,5 carriers for targeted drug delivery,6,7 tissue repair, and immunoassay, detoxification of 
biological fluids, hyperthermia,8 and in bio-separation, biosensors.9-14 There are many synthetic 
protocols for iron oxide nanoparticles like the co-precipitation method,15 thermal decomposition method, 
16 hydrothermal method,17 microemulsion method,18 Sonochemical method,19 and microwave assisted 
synthesis20 with their own merits and demerits which were previously reported.21 The average 
hydrodynamic diameter of these nanoparticles needs to be less than 100 nm to achieve targeted drug 
delivery and any other biomedical applications. On the other hand, there should also be a special 
surface coating which needs to be non-toxic and biocompatible and allows targeted drug delivery with 
a specific localization in the area. It was stated in a study that hydrophobic iron oxide nanoparticles, 
when entered the blood stream, are fenced by the hydrophobic plasma proteins through a process 
called as opsonization.22 After entering the physiological environment, there will be formation of a clump 
due to the contacts of hydrophobic-hydrophilic surfaces. This tends to clear the hydrophobic iron oxide 
nanoparticles through the process of mononuclear phagocytic system. In order to avoid this fast 
clearance from the system and to increase the stability, in vivo circulation, and functionality there is a 
need of hydrophilic coating on the surface of iron oxide nanoparticles. This makes the iron oxide 
nanoparticles a multifunctional theranostic agent by serving the purpose of both diagnosis and targeted 
therapy.  
1.2 Coating materials: There are several studies which used different kinds of coating 
materials on the surface of iron oxide nanoparticles. A) Chitosan, a natural polymer obtained from sea 
sources which is bio-compatible, hydrophilic, bio-degradable, non-antigenic and non-toxic coating on 
the iron oxide nanoparticles (IONPs) surface has shown that it was used to provide better contrast 
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agent for MR imaging and in therapeutic gene delivery.23-30 B) Polyethylene Glycol (PEG), a water 
soluble polymer which is reported to increase the aqueous solubility of hydrophobic drugs 31-34 and 
increases the circulation time by minimizing the uptake by the mononuclear phagocytic system. 35,36  It 
was also reported that PEG acts as a good spacer for the attachment of different biomolecules.37-42 C) 
Dextran, a polysaccharide which is known to be widely used in many biomedical applications, like MR 
imaging and commercially available contrast agents, and has been shown to process cancer nodal 
staging capabilities.43 Introducing a carboxy methyl group to the dextran coating improves the stability 
and functionality. A study was conducted on Porcine aortic endothelial cells in both 2D and 3D cell 
culture tests in which the cells were treated with 5 nm and 30 nm diameter IONPs coated with Dextran 
or PEG. The results showed that the cell viability was deceased upon treating with undecorated 
nanoparticles, whereas there was no reduction in cell viability when treated with Dextran and PEG 
coated IONPs. It was also stated that the undecorated nanoparticles induced significant formation of 
reactive oxidative species (ROS) and the IONPs coated with dextran or PEG did not increase the ROS 
levels. On the other hand, dextran and PEG coatings decreased the fluorescence intensity by 35.2% 
and 62.6% respectively.44 D) Poly (vinyl alcohol) which is a water soluble synthetic polymer has been 
successfully utilized for the drug delivery and other biomedical applications like tendon repair, 
ophthalmic materials, contact lenses etc. Because of having the properties of resisting protein 
adsorption and cell adhesion and high biocompatibility, it was reported to be used as an excellent 
coating material on the surface of IONPs. Different percentages of PVA coating on the IONPs surface 
using the anti-cancer drug Doxorubicin for drug delivery was studied by Kayal et.al.45 It was concluded 
that carboxy-PVA coating had excellent thermal stability and the amino-PVA had higher cellular uptake 
because of the negative charge of carboxylic acids and positive charge of amine groups respectively. 
E) Poly (vinyl pyrrolidone), a water-soluble polymer having neutral charge, aqueous solubility and 
biocompatibility has been coated on the surface of IONPs for use in different biomedical applications. 
The results from many studies showed there is an increase in the stability of IONPs in physiological 
media.46 It was stated that the PVP coated IONPs will be very encouraging for clinical applications 
because of their monodispersity and solubility. F) Poly (acrylic acid), synthetic high molecular weight 
polymer of acrylic acid is known to enhance the biocompatibility, stability of the nanoparticles and 
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facilitates the bioadhesion.47 G) Poly (Lactic-co-glycolic acid), PLGA, a co-polymer with biocompatibility 
and biodegradability, approved by Food and Drug Administration was used as a coating on the surface 
of iron oxide nanoparticles.48-50 
           1.3 Targeting ligands: Using the different nanoparticle systems for biomedical applications, 
there is a need of targeting ligands or specific proteins in derivatizing the IONPs. A) Transferrin, which 
is an iron-binding blood plasma glycoprotein, regulates the level of free iron in biological fluids. It is 
extensively used as a targeting ligand in the active pointing of anti-cancer agents, proteins, genes to 
mainly multiplying cells through transferrin receptors.51-54 B) TAT peptide derived from the Trans-
activator of transcription (TAT) of human immunodeficiency virus is a cell membrane-penetrating 
peptide which enhances the intracellular delivery.55,56 C) Folic acid, a water soluble B9 vitamin obtained 
from many sources like green leafy vegetables, liver, yeast etc. is used in treating megaloblastic 
anemia. In cancer therapy, folic acid acts as a common targeting ligand because of its poor 
immunogenic property and facilitates the internalization of particles due to the over expression of folate 
receptors on the cancerous cells.57 
  
         1.4 Cancer statistics:  According to the American Cancer Society, there are many estimated 
new cases and deaths in 2018 due to different types of cancer which is mentioned below in the tabular 
form, table 1. It was seen in the results that there were more number of new cases for prostate cancer 
compared to other cancer types, so nanoformulation was designed targeting the  prostate cancer. The 
most common type of cancer among men is the prostate cancer. The risk of prostate cancer is about 
6 in 10 men of age 65 or older are diagnosed with prostate cancer. According to the American cancer 
statistics, it was said that the average age of a person to be diagnosed with prostate cancer is about 
66 and very few people were diagnosed before the age of 40. After lung cancer, prostate cancer is the 
second leading cause of death in men.58 
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Table 1: Leading sites of new cancer cases and deaths- American Cancer Society facts and Figures 
2018 Estimates. 
            
             1.5 Nanotechnology in cancer:   A wide variety of nanotechnology-based approaches 
are available for the diagnosis and drug delivery. Different nanoplatforms including iron oxide 
nanoparticles (IONPs), gold nanoparticles (AuNPs), cerium oxide nanoparticles or nanoceria 
(CeONPs/NC), polymeric nanoparticles (PNPs), carbon nanotubes (CNTs) and quantum dots 
(QDs) play a vital role in biomedical applications.59-64 In addition, iron oxide nanoparticles have dual 
modalities of both MR detection and targeted drug delivery when conjugated with receptor targeting 
molecules or antibodies. These features prompted us to formulate magnetic nanomedicine (MnM) 
containing three drugs combination including irinotecan, oxaliplatin, and 5-fluorouracil to combat 
prostate cancer (Figure 1) 
Sites of cancer Estimated new cases 
in 2018 
Estimated deaths 
in 2018 
 
Prostate 
Lung & Bronchus 
Colon & Rectum 
Urinary bladder 
Kidney & Renal pelvis 
Liver & Intrahepatic bile duct 
Non-Hodgkin Lymphoma 
Leukemia 
 
164,690 
121,680 
75,610 
62,380 
42,680 
30,610 
41,730 
35,030 
 
29,430 
83,550 
27,390 
12,520 
10,010 
20,540 
11,510 
14,270 
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Figure 1. Schematic representation of mechanism of action of combination of three drugs for 
prostate cancer treatment. 
 
1.6 Triple Drug Regimen : Many studies have shown that the combination of three drug 
regimen of irinotecan, 5-Fluorouracil, oxaliplatin was well known to be effective in treating metastatic 
colorectal cancer65 and pancreatic cancer.66 The synergistic or additive interaction between SN-38 
(active metabolite of irinotecan) with oxaliplatin and 5-FU was reported in several studies.67-70 Having 
the dose limiting toxic effects and different mechanism of actions, the combination of irinotecan and 5-
FU, oxaliplatin and 5-FU, irinotecan and oxaliplatin have been broadly used in the clinical trials.71 
Several phase III studies indicated that the combinations of irinotecan and 5-FU/Leucovorin (FOLFIRI), 
oxaliplatin and 5-FU/Leucovorin (FOLFOX) have an increased therapeutic efficacy and antitumor 
activity when compared with 5-FU/Leucovorin alone.72-75 The results from phase III studies revealed 
that irinotecan when combined with 5-FU/LV has sustained the survival rates compared to 5-FU/LV 
alone.76 Also, it is reported that oxaliplatin in combination with 5-FU/LV as a first line chemotherapeutic 
regimen in a small group of unresectable metastatic colorectal cancer patients showed 30-40% survival 
without evidence of disease for more than 5 years.77,78 A randomized study on untreated metastatic 
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colorectal cancer patients indicated that patients were treated with FOLFIRI [irinotecan, leucovorin, and 
5-FU] followed by FOLFOX-6 [oxaliplatin, leucovorin, and 5-FU] on arm A and the reverse on arm B. 
The results from this study revealed there are similar therapeutic efficacies and the survival rates were 
21.5 months and 20.6 months for arm A and arm B, respectively. These suggests that the treatment of 
metastatic colorectal cancer patients with these three drugs is associated with promising survival.79 In 
another report, the FOLFOX-4 regimen [oxaliplatin, folinic acid, 5-Fluorouracil] had higher survival rates 
compared to IFL [irinotecan, 5-Fluorouracil, leucovorin], as only 24% patients on IFL were able to take 
oxaliplatin as a second line treatment, whereas 60% of the patients were able to receive irinotecan as 
the second line treatment on FOLFOX-4.80 To develop a new chemotherapy regimen with more 
therapeutic efficacy, the combination of irinotecan, oxaliplatin,5-fluorouracil was used as first line 
treatment in 42 metastatic colorectal cancer patients and the results of phase I-II studies showed there 
is 71.4% overall response rate, median progression free survival of 10.4 months and median overall 
survival rates of 26.5 months.81 The first line treatment of 31 metastatic colorectal cancer patients with 
irinotecan, oxaliplatin,5-fluorouracil achieved 58% overall response rate and adverse effects of 
neutropenia in 45% patients, 3-4 grade diarrhea in 32% patients.82 In a study, patients with advanced 
solid tumors given increasing doses of irinotecan, oxaliplatin followed by simplified LV/5-FU showed 
78% grade 3-4 neutropenia and 27% grade 3-4 diarrhea.83 Another study showed that 26 patients 
treated with irinotecan, oxaliplatin, 5-FU and leucovorin had adverse effects of 38% patients with grade 
3-4 neutropenia and 34% patients with grade 3-4 diarrhea.84 Many other studies reported the feasibility 
of this triple drug combination.85-87 It was indicated by several studies that the best results were attained 
in patients treated with all the three active agents (irinotecan, oxaliplatin, 5-fluorouracil) and synergistic 
effect was achieved by using in the order of irinotecan-oxaliplatin-5-fluorouracil.88 Phase III trials 
revealed higher survival rates, progression free-survival when irinotecan was administered along with 
the combination of 5-FU/leucovorin in comparison to 5-FU based regimens.72,73 A study with oxaliplatin 
stated that there is high response rate, time to tumor progression and survival rate when oxaliplatin is 
combined with 5-FU/LV.89 It was stated by a trial that infusional 5-FU regimens show low response 
rates compared to combination of infusional and bolus administration of 5-FU/LV alone.75,90 A study 
stated that adding oxaliplatin to 5-FU/Leucovorin progresses the outcome of patients with colorectal 
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cancer.89 Trials were carried out on using oxaliplatin and 5-FU in combination91,92 and compared with 
administration of oxaliplatin alone74 and 5-FU alone.75,90 A study was performed on the therapeutic 
activity of irinotecan in colorectal cancer patients which showed there is a noteworthy effect of 
irinotecan.72,73,75,93-96 Irinotecan when used as a first line drug showed more therapeutic efficacy as 5-
FU/LV.73 In a randomized study, irinotecan was combined with 5-FU/LV and the results were compared 
with 5-FU/LV alone. These studies reported longer time to progression, greater response rate in the 
combination therapy.72,73 The growth inhibitory effect was observed when oxaliplatin was administered 
after irinotecan.69 They also conducted a trial on sequential administration of irinotecan prior to 5-FU 
and observed a synergistic effect.67 Preclinical trials were performed on two drug combinations of 
oxaliplatin and irinotecan69, irinotecan, and 5-FU67,97,oxaliplatin and 5-FU.98,99 Phase II studies with the 
combination of 5-FU/LV with oxaliplatin showed that this combination prolonged the progression free 
survival.90,100-102 
Conclusion: In conclusion, based on above-mentioned results from pre-clinical trials and 
clinical trials, it was proven that the three anti-cancer agents (irinotecan, oxaliplatin, 5-fluorouracil, 
Figure 1) were effective in treating metastatic colorectal and pancreatic cancers.65,66 But due to the lack 
of targeted delivery, there are many side effects to the non-cancerous cells. To overcome this, a 
nanoformulation which can deliver drugs to the targeted sites was developed. As prostate cancer is the 
second leading cause of death in men,58 the synthesized nanoparticles were treated on human prostate 
cancer cell lines to check the similar therapeutic efficacy of the combination of three drugs (irinotecan, 
oxaliplatin, 5-fluorouracil). The results from our studies showed that the nanoformulation has minimal 
side effects on healthy cells and was very effective in treating prostate cancer.  
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CHAPTER II 
    
 
2.1 RESULTS AND DISCUSSION: 
         
 
2.1.1  Synthesis and characterization of IONPs: Polyacrylic acid-coated superparamagnetic iron 
oxide nanoparticles were synthesized using a water-based precipitation method as shown in [ 4.0 
× 10 -3 M (1, Scheme 1) ]  as reported previously.103 The iron oxide nanoparticles are known in 
biomedical applications like targeted drug delivery, immunoassay, detoxification of biological fluids, 
MRI tracker, treating hyperthermia, tissue repair, bio-separation and biosensors5-14. The 
synthesized IONPs were centrifuged to remove the bigger size IONPs. To get rid of the unreacted 
drugs and dye molecules, the resulting IONPs were purified using the dialysis method in a dialysis 
bag having molecular weight cut off range (MWCO of 6-8 kDa) as previously reported by Santra 
et, al.104 In order to use the IONPs for biomedical applications, an average size of below 100 nm is 
very important. So, we characterized the IONPs for average size and surface charge (zeta 
potential) using Zetasizer ZS90. The average size of the IONP-COOH was 41 ± 3 nm (Figure 2A) 
and the zeta potential was -24.3 mV (Figure 2B). For the addition of optical modality, 2.0 μL of 5 
μM fluorescent dye DiI was encapsulated in the IONP-COOH [2ml, 3.4 × 10 -3 M (2, Scheme 1)]. 
The IONP-COOH was  propargylated and pegylated in which the pegylation plays the role in 
enhancing the aqueous solubility of the drugs and also it was reported that PEG acts as a good 
spacer for the attachment of different biomolecules37-42 and the propargylation [2 ml, 3.0 × 10 -3 M 
(3, Scheme 1)] facilitates in performing “Click” chemistry by reacting with azide functionalized folic 
acid in presence of CuI as a catalyst [2 ml, 2.2 × 10 -3 M (4, Scheme 1)], as reported earlier.105 The 
folate functionalized IONPs plays a major role in targetability to the tumor. After successful 
conjugation of the targeting ligand, folic acid on the surface of IONP, they were characterized for 
hydrodynamic diameter and surface zeta potential. The average size of the folate functionalized 
IONP was found to be 46 ± 2 nm (Figure 2C) and the zeta potential was found to be -22.6 mV 
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(Figure 2D). To provide optical modality and therapeutic efficacy, the folate functionalized IONPs 
were encapsulated with 2.0 μL of 5 μM DiI dye [2.2 × 10 -3 M (2, Scheme 1)] and 5.0 μL of 2.0 mM 
irinotecan, 5.0 μL of 2.0 mM 5-Fluorouracil and 5.0 μL of 2.0 mM oxaliplatin [2.0 × 10 -3 M (5-8, 
Scheme 1)] using the solvent diffusion method.106 To get rid of the unreacted drugs and dye 
molecules, the folate functionalized IONPs carrying the therapeutic drugs and optical dye (IONP-
DiI-drugs-FOL) was dialyzed for 2 h against DI water by periodical water change. The dialyzed 
IONP-drugs-DiI-FOL was incubated on table mixer for 2 h at room temperature. It was labelled and 
stored at room temperature for further characterizations. The IONPs carrying drugs and dye (5-8, 
Scheme 1) was characterized for average size and zeta potential. The results were found to be 48 
± 2 nm (Figure 2E) and -23.1 mV (Figure 2F).  
 
            Scheme 1: Synthesis of biocompatible IONP-COOH (1) and encapsulated fluorescent dye 
using solvent diffusion method (2). Using EDC-NHS chemistry, the IONP-COOH was propargylated 
and pegylated (3). Using “Click” chemistry, IONP surface was conjugated with folic acid (4). 
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Therapeutic drugs irinotecan, 5-Fluorouracil, oxaliplatin and fluorescent dye DiI were encapsulated 
into the folate nanoparticles to formulate a personalized nanomedicine for the treatment of prostate 
cancer (5-8). 
To check the successful encapsulation of the drugs and dye and the conjugation of the 
surface functionality, the  UV-Vis and fluorescence spectrophotometric analysis was performed 
using a Tecan i-control plate reader. The specific absorbance and fluorescence bands (Figures 
3A & 3B) indicated the presence of folic acid . The absorption spectrum of FOL, DiI dye at 
wavelengths of 335 nm, 587 nm, respectively, was shown in Figure 3C. In Figure 3D, the presence 
of DiI dye at a fluorescence emission of 585 nm was observed. Figure 3E shows the presence of 
FOL, IRI at UV-Vis absorption wavelengths of 335 nm, 635 nm, and Figure 3F indicates the 
presence of IRI at a fluorescence emission at the wavelength of 680 nm. 
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       Figure 2: Dynamic light scattering experiments represents IONP-COOH, IONP-FOL and 
IONP-DiI-drugs-FOL with an average hydrodynamic diameter of 41 ± 3 nm , 46 ± 2 nm, and 48 ± 
2 nm, respectively, and the zeta potential of IONP-COOH , IONP-FOL and IONP-DiI-drugs-FOL 
are -24.3 mV , -22.6 mV, and -23.1 mV respectively. 
 
    Figure 3: (A) UV-Visible absorption (λabs= 335 nm) and (B) Fluorescence emission spectra 
(λmax= 450 nm) indicates the presence of folic acid in IONP-FOL. (C) UV-Visible absorption 
spectrum with bands at 335 nm, 587 nm shows the presence of folic acid, DiI dye respectively in 
IONP-DiI-FOL. (D) Fluorescence emission spectrum showing band at 585 nm indicates the 
presence of DiI dye in IONP-DiI-COOH. (E) UV-Visible absorption spectrum with bands at 335 nm, 
635 nm indicates the presence of folic acid, irinotecan respectively in IONP-DiI-drugs-FOL. (F) 
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Fluorescence emission spectrum with band at 680 nm indicates the presence of irinotecan in IONP-
DiI-drugs-FOL. 
The results from DLS showed that the iron oxide nanoparticles synthesized were having 
smaller size and the negative zeta potential which are ideal for the biomedical applications. In 
addition to that, the UV-Vis and fluorescence studies indicated the successful conjugation of the 
surface groups and encapsulation of drugs , fluorescent dye.  
2.1.2 Stability studies: Before treating the cells with the nanoparticles, the stability of the 
nanoparticles in different media including 1X PBS (pH = 7.4) and 10 % FBS was checked by 
measuring the average size of the nanoparticles at different time periods on 1 day, 7 days, 30 days, 
and 60 days. The results showed there was no much change in the size of the nanoparticles which 
indicates that the nanoparticles were stable with time.  
 
          Figure 4: Determination of stability of the nanoparticles in different media including 1X PBS 
(pH = 7.4) and 10 % FBS at different time points. Figure 4 (A) shows the stability of IONP-COOH 
and Figure (B) shows the stability of IONP-DiI-drugs-FOL. 
            The results indicated that the nanoparticles are very stable with time 
             2.1.3 In-vitro Cell viability (MTT assay): To know the therapeutic efficacy and cytotoxicity 
of the nanoparticles carrying our therapeutic drugs, concentration dependent cell viability assay or 
MTT assay was performed. The theory behind MTT assay is when the yellow colored MTT is added 
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to the cells treated with nanoparticles, a purple color formazan was formed. The intensity of the 
formazan formed is directly proportional to the amount of number of live cells. To perform MTT 
assay, both the cell lines Lymph node Carcinoma of Prostate Cancer (LNCaP) and PC3 cells were 
cultured and seeded in a 96 well plate on the previous day of experiment. The cells were incubated 
for 24 h at 37 ℃ in the presence of 5% CO2. On the day of experiment, the cells were treated with 
nanoparticles carrying the drugs individually and in combination (irinotecan+5-FU+oxaliplatin). 
After 24 h of incubation, MTT solution ( 30 μL , 5 mg/ml) was added in each well and incubated for 
4-6 hrs. The formazan crystal formed were dissolved using acidic solution ( 75 μL , 10 mL 
isopropanol + 250 μL HCl ) and the absorbance of the formazan formed was read using Tecan i-
control Plate reader. Very promising results were observed. There was about 85% of cell death in 
LNCaP cells (Figure 5A) within 24 h and very less cytotoxicity was seen in the PC3 cells (Figure 
5B) on treatment with different doses of the drugs individually and in combination. This experiment 
indicated that nanoparticles can deliver therapeutic drugs only to the cancer sites, when targeted.  
 
Figure 5: Determination of cytotoxicity within 24 h of incubation in LNCaP (A) and PC3 
cells (B) using MTT assay. A) It shows the concentration dependent cell death upon treatment with 
the drugs individually and in combination. B) Minimal or no toxicity was observed in PC3 cells when 
treated with nanoparticles carrying individual drugs and in combination. 
The results from MTT assay revealed the cell death upon the treatment of the LNCaP cells 
with nanoparticles and there is minimal toxicity in the control cell line, PC3 cells. 
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2.1.4 Intracellular uptake of cargos loaded IONPs: After observing the cytotoxicity of 
our nanoparticles carrying drugs on LNCaP cells, we were interested in visualizing the cell death. 
For that, cellular uptake studies were carried out on LNCaP cells and PC3 cells using nanoparticles 
with different functionalities. The cells were grown in petri dishes by supplying nutrient media and 
treated with nanoparticles. The cells were fixed using 4% paraformaldehyde and stained the 
nucleus with DAPI. The fluorescence microscopic images were obtained using IX73 Olympus 
microscope. The results showed non-internalization upon treating LNCaP with IONP-DiI-COOH 
Figures 6A-6D). The internalization of the nanoparticles was observed when the cells were treated 
with folate functionalized IONP carrying DiI dye. (Figures 6E-6H), and the cell death was noticed 
when the cells were treated with IONP-DiI-drugs-FOL (Figures 6I-6L). Also, PC3 cells were seeded 
as a control cell line and it was observed that folate nanoparticles were not internalized into PC3 
cells due to the lack of folate receptors. (Figures 6M-6P) 
 
 
             Figure 6: Fluorescence microscopic images in bright field and corresponding blue filter, 
red filter, and merged images. (A-D) showing non-internalization, (E-H) showing internalization, 
(I-L) showing cell death in LNCaP cells and (M-P) showing non-internalization in PC3 cells. 
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2.1.5 ROS generation in LNCaP cells: The results from cellular uptake studies made us 
to explore the literature for understanding the possible reason behind cell death. For this, we 
performed an in vitro assay known as ROS. ROS plays a major role in cell signaling pathway and 
hemostasis. In this experiment, a fluorescent dye named Dihydroethidium (DHE) was used. In 
theory, DNA dye DHE which is usually blue in color by itself  is oxidized to 2-hydroxyethidium in 
presence of ROS generation. The 2-hydroxyethidium gives red fluorescence. For this study, the 
LNCaP cells were seeded in 12-well plates and grown for 24 h. When the cells were 80-90% 
confluent, the nanoparticles were added and incubated for different time points at 6 h, 12 h, 24 h 
respectively. The cells were washed, stained with 32mM DHE dye and the fluorescence 
microscopic images of the cells were captured using an Olympus IX73 microscope. Figures 7A & 
7B showed the levels of ROS generation in cells at 6 h, Figures 7C & 7D at 12 h, and Figures 7E 
& 7F at 24 h of nanoparticle treatment in the bright field, and its corresponding red filter respectively. 
 
 
             Figure 7: Measure of ROS generation in LNCaP cells at different time points 6h, 12h, and 
24 h in bright field and corresponding red filter. 
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2.1.6 Apoptotic cell death in LNCaP cells: The generation of ROS eventually leads to 
apoptosis. Apoptosis is nothing but the programmed cell death in which the protrusion of plasma 
membrane occurs. This can be initiated by either intrinsic or extrinsic pathways. Here, the intrinsic 
pathway applies as the cells kills itself by sensing the stress. The basic principle behind apoptosis 
is phosphatidylserine (phospholipid component in the inner leaflet of the cell membrane) moves 
from inner leaflet to outer leaflet of the plasma membrane when the cells undergoes apoptosis. 
This acts as a signal for the macrophages to engulf the cell and leads to the cell death. To quantify 
the apoptotic cell death, a protein known as Annexin-V which has higher affinity towards 
phosphatidylserine labelled with a fluorescent dye FITC was used. The fluorescence emitted from 
the cells quantifies the cell death. To perform the apoptosis, the LNCaP cells were seeded in a 12 
well plate and treated with nanoparticles after attaining the 80-90% confluency. The cells were 
incubated with nanoparticles at different points in time: 6 h, 12 h, and 24 h, respectively. The cells 
were washed with PBS twice and stained with Annexin V-labelled FITC (5 µL) and Ethidium 
Homodimer III (5 µL) as stated in the Biotium protocol. Cells were washed twice with annexin V 
binding buffer and were fixed using 4% paraformaldehyde and observed under fluorescence 
microscope. The change in morphology of the cells was noticed as they became apoptotic and the 
population of the cells being reduced and getting washed away with time. The fluorescence images 
were obtained using Olympus IX73 Fluorescence microscope.  
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                Figure 8: Detection of apoptotic cell death in LNCaP cells at 6 h,12 h, and 24 h in the 
 bright field and FITC filters, respectively. 
 
               2.1.7 Comet assay: The results from all the above mentionedd studies showed there is 
cell death upon treating the cells with nanopraticles carrying drugs. As mentioned earlier, two of  
the drugs used in this project acts on DNA, to measure the extent of DNA damage possible through 
each of the drugs individually and  as a combination therapy we performed an in vitro assay known 
as Comet assay. The anti-cancer drugs used in this project were known to have the synergistic 
potential of damaging the DNA through different mechanisms.The basic principle behind comet 
assay is that, head indicates undamaged DNA and tail indicates the damaged DNA where the 
compact structure of DNA breaks down and migrates onto the agarose gel. When the cells were 
treated with irinotecan, lengthy tails were formed compared with 5-fluorourcail and oxaliplatin. Upon 
the treatment with oxaliplatin, there was no formation of comets as it was already known in literature 
that oxaliplatin acts through RNA biogenesis.106 The treatment of the cells with combination of the 
drugs, showed no distinct heads and all observed was the formation of tails because of the higher 
extent of DNA damage compared to the individual drug treatments.. 
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             Figure 9: Determination of extent of DNA damage through comet assay. Figures (A-D) 
indicates the extent of DNA damage when treated with irinotecan, 5-Fluorouracil, oxaliplatin and 
three drug combination. 
 
             The DNA damage was observed visually by staining the cells with a DNA dye named SYBR 
gold and capturing the fluorescent images of the comet slides using an Olympus X73 fluorescence 
microscope. The results showed the formation of comet, indicating that cancer cell death goes 
through DNA damage. The % of DNA damage is directly propotional to the tail DNA and the tail 
moment. When the cells were treated with drugs, the extent of DNA damage was quantitatively 
represented in the form of tail DNA and  tail moment using image J software. Figure 10 shows the 
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trend in tail DNA represented in blue upon the treatment of cells with combination of drgs, 
ironotecan, 5-FU and oxaliplatin. Tail moment in green shows irinotecan formed lengthy tails 
compared to 5-FU and oxaliplatin.  
 
  
             Figure 10: Tail DNA in blue and the tail moment in green indicates the extent of DNA 
damage on different drug treatments, irinotecan, 5-FU, oxaliplatin and combination of drugs. 
 
2.1.8 Migration assay: As we know that prostate cancer is highly metastatic, an in vitro 
cell based known as migration assay/invasion assay was performed to determine the anti-
metastatic potential of the anti-cancer drugs. The migration assay kit used in this assay contains 
two chambers, upper invasion chamber and lower feeder tray. The invasion chamber is coated with 
collagen through which the cells migrates from invasion chamber to feeder tray.  This kit mimics 
the metastases process which happens in the body. The cells were treated with different drugs and 
incubated at 37 ℃ in presence of 5 % CO2. Upon incubation with drugs, the migratory cells move 
from invasion chamber into the into the feeder tray through the collagen layer. The migratory cells 
were stained with a fluorescent dye named CyUQANT. The anti-metastatic potential of the drugs 
 21 
 
was determined through the fluorescence intensity measured using Tecan i-control plate reader. 
The results proved that after incubation with drug(s), migration capability of the cells tremendously 
reduced, as lesser fluorescence emission was collected from the feeder tray in the experiment. 
Taken together, the three anti-cancer drugs we used were highly anti-metastatic. 
 
             Figure 11: Determination of anti-metastatic potential using migration assay. Control cells 
in green showed the maximum invasion, whereas the cells treated with IONPs carrying combination 
of drugs in red, showed minimal invasion. The IONPs carrying individual drugs in yellow, blue, and 
grey showed more invasion compared to the combination treatment. 
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2.2 EXPERIMENTAL SECTION: 
2.2.1 Materials: Iron salts (ferric chloride hexahydrate, ferrous chloride tetrahydrate), 
hydrochloric acid and ammonium hydroxide, Phosphate buffer saline (PBS) were ordered from 
Fischer Scientific. Polyacrylic acid (PAA), propargyl amine (PA), dimethylsulfoxide (DMSO), 3-(4, 
5-dimethylthiazol-2-yl) - 2, 5-diphenyltetrazolium bromide (MTT), N-hydroxysuccinimide (NHS) 
were attained from Sigma-Aldrich. Near infrared dye (DiI-D282), and 4, 6-diamidino-2-phenylindole 
(DAPI-D1306) were ordered from Invitrogen. [1-ethyl-3- [3- (dimethyl amino) propyl] carbodiimide 
hydrochloride] (EDC) was obtained from Pierce Biotechnology. MES sodium salt was purchased 
from Acros Organics. The three anti-cancer drugs irinotecan, 5-Fluorouracil, oxaliplatin were 
acquired from Sigma Life Sciences. Dihydroethidium (DHE) was bought from Cayman 
Laboratories. Apoptosis and necrosis quantification kit was purchased from Biotium. SYBR gold 
nucleic acid gel stain was ordered from Fischer Scientific. Paraformaldehyde was purchased from 
Electron Microscopic Sciences. The human prostate cancer cell line LNCaP and (PC3) were 
obtained from ATCC. RPMI-1640 medium and Kaighn’s modification of Ham’s F12K medium were 
purchased from Corning Life Sciences. Comet assay kit, Lysis solution and LM agarose were 
acquired from Trevigen. Migration assay kit was purchased from Millipore. 
2.2.2 Instrumentations: Using Malvern Zetasizer Nano ZS90, the average size and zeta 
potential of nanoparticles were measured. A Tecan Infinite M200PRO plate reader was used to 
study UV/Vis measurements, the absorbance of MTT, and the fluorescence of Migration assay. An 
Olympus IX73 Fluorescence microscope was used to capture the images of cellular uptake studies, 
ROS, apoptotic studies and Comet assay.  
2.2.3 Synthesis of PAA coated IONPs (1): Iron oxide nanoparticles (IONPs) coated with 
PAA were synthesized using “water-based precipitation method”. To synthesize PAA coated 
IONPs, three solutions were prepared. i) Iron salts solution (0.7 g of FeCl3.6 H2O and 0.4 g of FeCl2 
.4H2O in 100 μL of 12 N HCl and 2 mL of DI H2O), ii) an alkaline solution (1.8 mL of 30% NH4OH 
solution in 15 mL of deionized water) and iii) stabilizing agent solution (2 g of PAA in 5 mL of DI 
water). The synthetic procedure was as follows: The solution of iron salts was added into alkaline 
solution. Afterwards, stabilizing agent (PAA in DI water) was added, and the reaction was continued 
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at a speed of 4000 rpm. Then, the resulting IONPs were centrifuged at 3000 rpm, 4000 rpm and 
4000 rpm for 20 min each, respectively. The supernatant obtained after the final centrifugation was 
dialyzed in a dialysis bag has a molecular weight cut off range of 6-8 kDa. The dialysis process 
was done in beaker with DI water and a magnetic stirrer. The water was changed periodically for 
24 h and the dialyzed IONPs were taken out of dialysis, labelled, and stored. 
2.2.4 Encapsulation of DiI dye into IONPs (2): Using the solvent diffusion method, 2μL 
of 5 μM DiI dye, 5 μL of 2 mM irinotecan, 5 μL of 2 mM 5-fluorouracil and 5 μL of 2 mM oxaliplatin 
were encapsulated into 2 mL of PAA coated IONPs dropwise at a vortexing speed of 2000 rpm at 
intervals of time without formation of any precipitate. The drugs and dye encapsulated IONPs were 
set aside on table mixer at room temperature for 2 h of incubation and then dialyzed to get rid of 
the unreacted drugs and dye molecule. The dialyzed IONPS carrying cargos were stored at room 
temperature.  
2.2.5 Synthesis of Propargylated IONPs (3a): Water soluble Carbodiimide chemistry 
(CDI) was used to prepare Propargylated IONPs and the synthetic protocol we used was as follows: 
i) 30 mg of EDC [1-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride] in 250 μL of MES 
buffer (pH 6.0), ii) 22 mg of NHS [2-(N-morpholino) ethane sulfonic acid] in 250 μL of MES buffer 
(pH 6.0) and iii) 5 mg of propargyl amine in 500 µL of DMSO were weighed. 5 mL of IONPs were 
taken and the EDC 
 in MES buffer was added directly and mixed, NHS in MES buffer was added in 4 parts 
with proper mixing, and the resulting solution was kept on table mixer for 3 min of incubation. 
Propargyl amine in DMSO was added dropwise with proper mixing and without any precipitation. 
The resulting propargylated nanoparticles were kept on table mixer overnight and dialyzed against 
DI water for 2 h to get rid of the unreacted materials. 
2.2.6 Synthesis of azide functionalized folic acid (3b): For this synthesis, i) 22 mg EDC 
[1-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride] in 250 μL MES buffer (pH 6.0), ii) 
13 mg NHS [2-(N-morpholino) ethane sulfonic acid] in 250 μL MES buffer (pH 6.0) and iii) 2.5 mg 
of amino propyl azide in a mixture of 200 μL DI water and 200 μL DMSO were weighed. 10 mg of 
folic acid was dissolved in 5 mL of 1X PBS and added EDC in MES buffer directly with proper 
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mixing. NHS in MES buffer was added in 4 parts with good mixing and the resulting solution was 
incubated for 3 min on table mixer. Amino propyl azide in the mixture of DI water and DMSO was 
added dropwise without any precipitation. The resulting solution was kept on the table mixer 
overnight.  
2.2.7 Synthesis of folate conjugated IONPs (4): Folate conjugated IONPs were 
synthesized by adding 1.5 mL azide functionalized folic acid to 4 mL of propargylated IONPs.  To 
the above liquid mixture, 50 μL of CuI was added from a solution of 1 mg CuI dissolved in 250 μL 
of DMSO. The folate conjugated IONPs were kept on table mixer overnight and dialyzed against 
DI water for 2 h. After the dialysis, the UV-Vis studies were performed. The presence of absorption 
and fluorescence peaks at 360 nm and 455 nm, respectively, which indicated the folate ligands 
were successfully conjugated on the surface of IONPs (Figure 3A & 3B). 
2.2.8 Synthesis of drugs, dye-encapsulating functional IONPs: After the successful 
conjugation of folate ligands on the IONPs surface, our therapeutic drugs and fluorescent dye 
were encapsulated into the IONP-FOL using solvent diffusion method. 2 mL of IONP-FOL was 
taken and encapsulated with 2 μL of 5 μM DiI dye (2, Scheme 1), 5 μL of 2 mM irinotecan, 5 μL 
of 2 mM 5-Fluorouracil and 5 μL of 2 mM oxaliplatin using Solvent diffusion method (5, Scheme 
1). The drugs and the optical dye were dissolved in DMSO and added dropwise at a speed of 
1500 rpm on a vortex mixer. The encapsulated nanoparticles were incubated on table mixer for 2 
h, purified by dialysis for 2 h. The successful encapsulation of the drugs and dye was confirmed 
by performing the UV-Vis studies. 
2.2.9 Cytotoxicity study (MTT assay): The Human prostate cancer cells (LNCaP) and 
(PC3) were purchased from ATCC. Both the cell lines (LNCaP and PC3) were grown in 89% RPMI 
1640 and Kaighn’s modification of Ham’s F12K medium purchased from Corning Life Sciences. 
Both the media were prepared by mixing 89% media with 10% fetal bovine serum (Corning Life 
Sciences), and 1% Penicillin-Streptomycin antibiotic solution (10000 I.U/mL Penicillin and 10000 
μg/mL Streptomycin). The cells were cultured in an incubator at 37 oC with 5% CO2. When the cells 
were confluent, they were seeded in 96-well plate (2500 cells /well) on the day before the 
experiment and incubated for 24 h. On the next day, cells were incubated with drug encapsulated 
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IONPs for 24 h at 37 oC. The cells were treated with nanoparticles carrying individual drugs and in 
combination.  After that, cells were washed twice with 1X PBS and added 30 µL MTT (5 mg/mL) 
solution to each well and incubated at 37 oC for 4-6 h. Depending on the %cell viability, Formazan 
crystals were formed within this 4-6 h. The formazan crystals formed were dissolved in acidic 
solution (10 mL isopropanol + 250 µL 12 N HCl). The absorbance was read at a wavelength of 570 
nm using an infinite M200 PRO microplate reader. Very promising results were observed. There 
was about 85% of cell death in LNCaP cells (Figure 4A) within 24 h and very less cytotoxicity was 
seen in the PC3 cells (Figure 4B). It was proved that the targeted drug delivery was achieved 
through our nanoformulation. 
2.3.0 Cellular uptake studies by fluorescence microscopy: Olympus IX73 fluorescence 
microscope was used to observe the cellular uptake using fluorescence imaging. Both the cell lines, 
LNCaP and PC3 were seeded in petri dishes on the previous day of the experiment. The cells were 
checked under the microscope for the confluency. When the cells were confluent, they were treated 
with specific functional nanoparticles for internalization, non-internalization, cell death studies and 
incubated at 37 oC for 24 h. Then, the cells were washed with 1X PBS twice and fixed with 4% 
formaldehyde for 10 min. The cell nuclei were stained with DAPI dye for 15 min away from the light. 
The non-internalization (Figures 5A-5D), internalization (Figures 5E-5H) and cell death (Figures 
5I-5L) in LNCaP and non-internalization in PC3 cells (Figures 5M-5P) were seen by capturing the 
images of the dishes in bright field, blue filter, red filter and merged images. 
2.3.1 Assessing the levels of ROS generation in LNCaP cells: To study the measure 
of reactive oxidative species generation in LNCaP cells, the LNCaP cells were seeded in a 12 well 
plate and incubated for 24 h. After the cells were 80-90% confluent, the nanoparticles and 
incubated for different time points at 6 h, 12 h, 24 h, respectively, and the cells were washed with 
1X PBS. The fluorescent dye DHE (300 μL of 32 mM) dye purchased from Cayman laboratories 
was added to the cells. The 12 well plate was kept in hood for 30 min and washed twice with 1X 
PBS after staining.  Then 4% paraformaldehyde was added for fixation and placed in hood for 10 
min. The cells were washed and covered with 1X PBS. Then the images in bright field and red filter 
were captured using fluorescence microscope (Figure 6). 
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2.3.2 Quantification of apoptotic cell death in LNCaP cells: The cell death was 
quantified by the apoptosis and necrosis quantification kit obtained from Biotium. On the previous 
day of experiment, LNCaP cells were seeded in a 12 well plate. After attaining 80-90% confluency, 
the cells were incubated with nanoparticles at different time points: 6 h, 12 h and 24 h at 37oC 
incubator with 5% CO2. The cells were washed with PBS twice and stained with Annexin V-FITC 
(5 µL) and Ethidium Homodimer III (5 µL) as stated in the Biotium protocol. Cells were washed 
twice with annexin V binding buffer and were fixed using 4% paraformaldehyde. Finally, the cells 
were washed with annexin V binding buffer twice. The images in bright field and green filter at 
different time points 6 h, 12 h and 24 h were captured using Olympus IX73 fluorescence microscope 
(Figure 7). 
2.3.3 Measure of DNA damage (Comet assay): The mixture of 50 μL LNCaP cells 
(1×105/ml) and 500 μL of molten LM agarose was taken. From this, 100 μL was placed on each 
well of the pretreated comet slides. The slides were placed at in dark for 30 min. The slides were 
then immersed in lysis solution purchased from Trevigen, overnight at 4 ℃ and the excess buffer 
was drained out from the slides. The slides were now placed in freshly prepared alkaline unwinding 
solution (pH>13), followed by alkaline electrophoresis by placing slide tray adjacent to black 
cathode at 21 Volts for 30 min. The excess electrophoresis solution was taken out from the slides 
and the slides were immersed gently twice in deionized water for 5 min each and then in 70% 
ethanol for 5 min. The slides were placed on thermo mixer at 37 ℃ for 10-15 min and stained with 
100 μL of diluted SYBR gold onto each well. Then the slides were taken from thermo mixer and 
rinsed in deionized water to get rid of excess dye; the slides were dried and fluorescent images 
were captured using IX73 Olympus fluorescence microscope. 
2.3.4 Detection of anti-metastatic potential (Migration assay): The mixture of 6 mL 
0.5% FBS (0.5 mL FBS+42.5 mL RPMI 1640 media + 2 mL ABAM) with 1/4th of the cell pellet was 
resuspended well and incubated for 24 h in a 70 mL flask. The next day, the cells were checked 
and found to be healthy. The cells were washed with 1X PBS twice and 5 mL of harvesting buffer 
was added. This was incubated for 5 min and 5 mL of quenching media was added to stop the 
action of trypsin. The entire solution was taken into a centrifuge tube and centrifuged at 1000 rpm 
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for 6 min. The quenching media was then added to the cell pellet and resuspended well. From this 
suspension, 100 μL was added to 30 μL of nanoparticles. The invasion chamber of the migration 
assay kit was rehydrated with 100 μL of 0% FBS media. After the rehydration time, 75 μL of the 
media was taken out of each well without touching the collagen layer. In the feeder tray, 150 μL of 
10% FBS was added and the 100 μL of the samples (cell suspension with nanoparticles) were 
added in the invasion chamber and incubated for 24 h. On the next day, 150 μL of cell detachment 
buffer was added in each well of the invasion chamber with samples. The samples were taken out 
of the invasion chamber and placed in the wells of a 96 well plate and incubated for 30 min at 37 
℃. The feeder tray was taken out and cleaned the wells with DI water. After 30 min of incubation, 
50 μL of lysis buffer and dye solution (1:75 ratio of dye and Lysis solution) was added and kept in 
hood for 15 min away from light. Then, 100 μL of the sample was transferred to a new well of the 
96 well plate and measured the fluorescence intensity at a wavelength of 480/520 nm using Tecan-
i control plate reader. 
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                                                                 CHAPTER III 
 
 
                                          CONCLUSION AND FUTURE DIRECTION 
 
 
In conclusion, it is known that prostate cancer is highly metastatic and the conventional 
treatment routes were not effective in showing the positive results. Because nanotechnology-based 
drug delivery systems have been very successful in cancer therapy, nanoformulations were 
designed, which has the capability of both targeting and treating prostate cancer. There were 
several reasons for the failure of numerous treatment options, including toxicity of drugs to the non-
cancerous cells, multi-drug resistance etc. The use of the nanotechnology-based drug delivery 
systems in cancer therapies has been very efficacious due to their small hydrodynamic diameter 
(10-100 nm), which facilitates the targeted drug delivery and many other biomedical applications 
possible. Altogether, drug delivery through nanoformulation keeps the drug safe from degradation 
outside the target site.   
In this study, we have formulated new nanotheranostic drug delivery system in the targeted 
treatment only to prostate cancer cells to enhance the effectiveness of conventional anti-cancer 
agents and to improve their toxic effects. We have synthesized iron oxide nanoparticles coated with 
PAA using water-based precipitation method. The surface of synthesized IONPs was decorated 
with folic acid (targeting ligand for folate receptor) and the anti-cancer drugs and optical dye were 
encapsulated via solvent diffusion method. The resulting drugs and dye carrying nanoparticles were 
purified using dialysis and characterized. The three drugs irinotecan, oxaliplatin, 5-Fluorouracil 
were used in this study to assess the therapeutic potential of their combination. 
Different cell-based assays were performed. The prostate cancer cell line (LNCaP) was 
treated with this nanoparticle and the % cell viability was observed through MTT assay. The results 
showed about 85% of cell death within 24 h upon treatment of nanoparticle carrying three drug 
combination.  Minimal toxicity was observed on the PC3 cell line when treated with nanoparticles 
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carrying drugs. This result specified that the functionalized nanoparticle was successful in 
accomplishing targeted drug delivery. The results from cellular uptake studies showed the 
nanoparticles achieved targeted drug delivery minimizing the toxic effects to the healthy cells. Also, 
the results from ROS and apoptosis showed that the nanoparticle system with anti-cancer drugs 
was capable of enhancing the oxidative stress in the cancer cells and causing cell death. The 
results from Comet assay showed these anti-cancer drugs have the capability of damaging DNA 
through different mechanisms. The migration assay results indicated these anti-cancer drugs have 
the anti-metastatic potential, which is crucial in treatment of prostate cancer. Taken together, the 
newly formulated nanomedicine would have tremendous effect in the targeted treatment of prostate 
cancer in clinical settings. 
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